2025年股份计划旨在吸引及挽留对本集团长期发展及成功作出重要贡献的参与人士，表彰并奖励参与人 士过去对本集团的贡献，为参与人士提供收购本公司专有权益的机会，并鼓励参与人士进一步为本公司 作出贡献，致力提升本公司及其股份的价值，从而造福本公司及其全体股东。2025年股份计划将为本公 司提供灵活的方式，以挽留、激励、奖励、酬劳、补偿参与人士及╱或为彼等提供福利。 智通财经APP讯，映恩生物-B(09606)发布公告，于2025年12月13日，映恩生物(本公司，连同其附属公 司统称本集团)的董事会议决建议采纳2025年股份计划，惟须经本公司股东批准方可作实。 ...

映恩生物-B(09606)发布公告，于2025年12月13日，映恩生物(本公司，连同其附属公司统称本集团)的董 事会议决建议采纳2025年股份计划，惟须经本公司股东批准方可作实。 2025年股份计划旨在吸引及挽留对本集团长期发展及成功作出重要贡献的参与人士，表彰并奖励参与人 士过去对本集团的贡献，为参与人士提供收购本公司专有权益的机会，并鼓励参与人士进一步为本公司 作出贡献，致力提升本公司及其股份的价值，从而造福本公司及其全体股东。2025年股份计划将为本公 司提供灵活的方式，以挽留、激励、奖励、酬劳、补偿参与人士及╱或为彼等提供福利。 ...

智通财经APP讯，中国健康科技集团(01069)发布公告，于2025年12月9日，董事会决议建议采纳股份计 划(须待股东批准后，方可作实)，以令本公司进一步将其董事及主要雇员的长远利益与本公司利益保持 一致，并激励彼等持续推动本公司的增长及发展。 ...

股份计划将根据上市规则第十七章构成一项股份计划。采纳股份计划须待(a)股东于股东周年大会上通 过普通决议案，以批准采纳股份计划；及(b)联交所上市委员会批准根据股份计划项下授出的购股权行 使或股份奖励归属而将予配发及发行的新股份上市及买卖获达成后，方可作实。 格隆汇12月9日丨中国健康科技集团(01069.HK)公告，于2025年12月9日，董事会决议建议采纳股份计划 (须待股东批准后，方可作实)，以令公司进一步将其董事及主要雇员之长远利益与公司利益保持一致， 并激励彼等持续推动公司之增长及发展。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 SITC International Holdings Company Limited 1308 (1)截至二零二五年九月三十日止九個月的未經審核經營數據 及 (2)有關二零二四年年報的補充公告 截至二零二五年九月三十日止九個月的未經審核經營數據 於年報日期，根據股份計劃可發行的股份總數為264,347,788股，相當於本公 司於該日期已發行股本約9.84%。 承董事會命 海豐國際控股有限公司 海豐國際控股有限公司（「本公司」，連同其附屬公司統稱「本集團」）董事（「董 事」）會（「董事會」）謹此公佈本集團截至二零二五年九月三十日止九個月的若干 未經審核經營數據及二零二四年同期的比較數字。 本集團的收入由截至二零二四年九月三十日止九個月的約2,108.5百萬美元增加 約16.6%至截至二零二五年九月三十日止九個月的約2,458.9百萬美元。截至二 零二五年九月三十日止九個月，本集團的集裝箱運量為2,749 ...

Group 1 - The core point of the article is that Jinxin Reproductive Medicine (01951) has proposed a 2025 Share Option Plan, which aims to align the long-term interests of the company's directors and key employees with those of the company, thereby incentivizing them to drive growth and development [1] - The 2025 Share Option Plan will constitute a share option scheme funded through the issuance of new shares, in accordance with Chapter 17 of the Listing Rules [1] - On September 25, 2025, the board resolved to grant a total of 137,235,000 share options to the management under the 2025 Share Option Plan, subject to conditional approval from independent shareholders at a special general meeting [1] Group 2 - Additionally, the board plans to grant a total of 2,400,000 share options and 1,200,000 restricted shares to non-executive participants under the 2025 Share Option Plan [1]

Core Viewpoint - The company proposes the adoption of the 2025 Share Option Plan, aimed at aligning the long-term interests of its directors and key employees with those of the company, thereby incentivizing them to drive growth and development [1] Summary by Sections Share Option Plan - The 2025 Share Option Plan is subject to shareholder approval and will constitute a share scheme funded through the issuance of new shares in accordance with the Listing Rules Chapter 17 [1] - On September 25, 2025, the board resolved to grant a total of 137,235,000 share options to the management under the 2025 Share Option Plan, with conditional grants to Mr. Dong Yang pending independent shareholder approval at a special general meeting [1] - Additionally, the plan includes the granting of 2,400,000 share options and 1,200,000 restricted shares to non-executive participants [1]

永利澳门(01128)发布公告，于2025年9月1日，该公司就根据股份计划授予参与人(发行人的董事除外)的 股份奖励或期权而发行5万股。 ...

Core Viewpoint - Yicheng Group (08365.HK) announced a proposal to update the existing general mandate for the board to issue and deal with new shares equivalent to 20% of the company's issued share capital as of the date of the special general meeting [1] Group 1 - The board's proposal requires approval from independent shareholders at a special general meeting through an ordinary resolution [1] - The new general mandate is in compliance with the revised GEM Listing Rules effective from January 1, 2023, specifically Chapter 23 [1] - The share scheme proposed by the board also requires shareholder approval at the special general meeting to take effect [1]

Core Viewpoint - The board of Yichen Group (08365.HK) proposes to update the existing general mandate to allow the issuance of new shares equivalent to 20% of the company's issued share capital as of the date of the special general meeting [1] Group 1 - The new general mandate requires approval from independent shareholders at a special general meeting through an ordinary resolution [1] - The board recommends adopting a share scheme to comply with the revised GEM Listing Rules effective from January 1, 2023 [1] - The share scheme will also require approval from shareholders at the special general meeting before it can be implemented [1]